Laura Chico
Stock Analyst at Wedbush
(3.71)
# 881
Out of 5,113 analysts
226
Total ratings
48.8%
Success rate
8.3%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Outperform | $16 → $19 | $7.89 | +140.81% | 15 | Jan 21, 2026 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $32 → $36 | $29.51 | +21.99% | 9 | Jan 12, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Underperform | $83 → $95 | $314.75 | -69.82% | 11 | Jan 12, 2026 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $46 | $50.20 | -8.37% | 11 | Dec 22, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $31 → $30 | $21.25 | +41.18% | 10 | Dec 11, 2025 | |
| VERA Vera Therapeutics | Maintains: Neutral | $23 → $33 | $46.75 | -29.41% | 9 | Dec 11, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $42 → $47 | $33.54 | +40.13% | 8 | Dec 10, 2025 | |
| PHVS Pharvaris | Maintains: Outperform | $27 → $30 | $27.18 | +10.38% | 8 | Nov 13, 2025 | |
| MAZE Maze Therapeutics | Maintains: Outperform | $35 → $36 | $45.34 | -20.60% | 2 | Nov 7, 2025 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $35 → $32 | $29.36 | +8.99% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $11 | $3.67 | +199.73% | 3 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $8 | $5.60 | +42.86% | 12 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $18 | $16.05 | +12.15% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $6.57 | +113.09% | 3 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $43 | $42.41 | +1.39% | 9 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $32 | $30.03 | +6.56% | 12 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $2.64 | +89.39% | 6 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $137 → $141 | $133.89 | +5.31% | 10 | Jul 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $34 | $24.62 | +38.10% | 13 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $6.76 | +166.27% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $121 | $174.12 | -30.51% | 18 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $4 | $16.81 | -76.20% | 4 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $3 | $1.81 | +65.75% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $29 | $21.81 | +32.97% | 14 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.94 | +77.66% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.64 | +1,618.48% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $10.59 | -52.79% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $56.85 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $4.76 | +5.04% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $12.67 | +1,072.06% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $9.50 | +7,478.95% | 1 | Jan 19, 2018 |
Ardelyx
Jan 21, 2026
Maintains: Outperform
Price Target: $16 → $19
Current: $7.89
Upside: +140.81%
Stoke Therapeutics
Jan 12, 2026
Maintains: Outperform
Price Target: $32 → $36
Current: $29.51
Upside: +21.99%
Praxis Precision Medicines
Jan 12, 2026
Maintains: Underperform
Price Target: $83 → $95
Current: $314.75
Upside: -69.82%
Dianthus Therapeutics
Dec 22, 2025
Reiterates: Outperform
Price Target: $46
Current: $50.20
Upside: -8.37%
Denali Therapeutics
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $21.25
Upside: +41.18%
Vera Therapeutics
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $46.75
Upside: -29.41%
Viridian Therapeutics
Dec 10, 2025
Maintains: Outperform
Price Target: $42 → $47
Current: $33.54
Upside: +40.13%
Pharvaris
Nov 13, 2025
Maintains: Outperform
Price Target: $27 → $30
Current: $27.18
Upside: +10.38%
Maze Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $36
Current: $45.34
Upside: -20.60%
Edgewise Therapeutics
Nov 7, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $29.36
Upside: +8.99%
Sep 30, 2025
Maintains: Outperform
Price Target: $15 → $11
Current: $3.67
Upside: +199.73%
Sep 30, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $5.60
Upside: +42.86%
Aug 14, 2025
Maintains: Outperform
Price Target: $17 → $18
Current: $16.05
Upside: +12.15%
Aug 13, 2025
Maintains: Outperform
Price Target: $17 → $14
Current: $6.57
Upside: +113.09%
Aug 12, 2025
Maintains: Outperform
Price Target: $42 → $43
Current: $42.41
Upside: +1.39%
Aug 7, 2025
Maintains: Outperform
Price Target: $30 → $32
Current: $30.03
Upside: +6.56%
Aug 6, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $2.64
Upside: +89.39%
Jul 31, 2025
Maintains: Outperform
Price Target: $137 → $141
Current: $133.89
Upside: +5.31%
Jul 14, 2025
Maintains: Neutral
Price Target: $35 → $34
Current: $24.62
Upside: +38.10%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $6.76
Upside: +166.27%
Jun 12, 2025
Reiterates: Neutral
Price Target: $121
Current: $174.12
Upside: -30.51%
May 15, 2025
Reiterates: Neutral
Price Target: $4
Current: $16.81
Upside: -76.20%
Mar 12, 2025
Maintains: Outperform
Price Target: $4 → $3
Current: $1.81
Upside: +65.75%
Mar 3, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $21.81
Upside: +32.97%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.94
Upside: +77.66%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.64
Upside: +1,618.48%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $10.59
Upside: -52.79%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $56.85
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $4.76
Upside: +5.04%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $12.67
Upside: +1,072.06%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $9.50
Upside: +7,478.95%